A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Saracatinib (Primary) ; Zoledronic acid
- Indications Bone metastases
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors AstraZeneca
- 31 Jan 2012 Planned end date changed from 1 Sep 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 27 May 2011 Planned end date changed from 1 Jul 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date changed from 1 Apr 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.